Point72 Asset Management L.P. Buys 219,329 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST)

Point72 Asset Management L.P. grew its holdings in LifeStance Health Group, Inc. (NASDAQ:LFST - Free Report) by 24.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,100,441 shares of the company's stock after buying an additional 219,329 shares during the period. Point72 Asset Management L.P. owned 0.29% of LifeStance Health Group worth $7,703,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in LFST. Dimensional Fund Advisors LP lifted its holdings in shares of LifeStance Health Group by 82.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company's stock worth $4,991,000 after buying an additional 457,930 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in LifeStance Health Group during the 3rd quarter worth $3,150,000. Charles Schwab Investment Management Inc. raised its holdings in LifeStance Health Group by 36.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,104,453 shares of the company's stock valued at $7,731,000 after acquiring an additional 297,723 shares in the last quarter. Principal Financial Group Inc. increased its position in shares of LifeStance Health Group by 6.1% in the third quarter. Principal Financial Group Inc. now owns 4,116,766 shares of the company's stock worth $28,817,000 after purchasing an additional 235,316 shares during the period. Finally, Jennison Associates LLC grew its stake in LifeStance Health Group by 9.5% during the third quarter. Jennison Associates LLC now owns 2,136,942 shares of the company's stock worth $14,959,000 after buying an additional 184,896 shares in the last quarter. Institutional investors own 85.50% of the company's stock.

Insider Activity at LifeStance Health Group

In related news, Director Robert Bessler sold 75,000 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $7.54, for a total value of $565,500.00. Following the transaction, the director now owns 1,424,447 shares in the company, valued at $10,740,330.38. The trade was a 5.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 6.60% of the stock is currently owned by company insiders.

LifeStance Health Group Trading Up 1.7 %

NASDAQ LFST traded up $0.12 on Friday, hitting $7.34. The company's stock had a trading volume of 1,194,325 shares, compared to its average volume of 1,993,428. The firm has a market cap of $2.81 billion, a PE ratio of -28.23 and a beta of 1.28. The company's 50-day moving average is $7.13 and its 200 day moving average is $6.28. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of 0.19. LifeStance Health Group, Inc. has a 1-year low of $4.64 and a 1-year high of $9.20.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.66% and a negative net margin of 7.90%. The business had revenue of $312.70 million during the quarter, compared to analyst estimates of $302.25 million. During the same period last year, the company earned ($0.17) EPS. LifeStance Health Group's revenue for the quarter was up 18.9% compared to the same quarter last year. As a group, analysts predict that LifeStance Health Group, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LFST has been the subject of a number of research reports. UBS Group dropped their target price on shares of LifeStance Health Group from $9.00 to $7.50 and set a "neutral" rating for the company in a report on Thursday, August 15th. Barclays increased their price target on LifeStance Health Group from $6.00 to $7.00 and gave the company an "underweight" rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat, LifeStance Health Group presently has an average rating of "Hold" and an average price target of $8.50.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.